Roche's Gazyva Wins First-Ever FDA Approval for Primary Membranous Nephropathy

Patients with a rare kidney disease that can end in kidney failure now have an approved treatment where none existed before.

Sources

Sources & evidence

What “Source checked” means

The FDA approved Roche's Gazyva on Friday as the first treatment ever cleared for primary membranous nephropathy, a rare kidney disease.

Genentech, a member of the Roche Group, announced the approval on Monday, November 16. The Food and Drug Administration (FDA) acted on Friday, November 13, 2026.

A first approved option for a rare disease

The approval covers adults with primary membranous nephropathy (pMN) at risk of disease progression. Gazyva (obinutuzumab) is approved to induce remission of proteinuria, the leaking of protein into urine.

The FDA called Gazyva the first drug approved specifically for this disease. Genentech called it the first and only therapy approved for primary membranous nephropathy.

In pMN, the immune system attacks the glomeruli, the kidney's tiny filtering units. Protein leaks into the urine, and kidney function can decline gradually toward failure.

The disease is rare, with an estimated incidence of 1.2 cases per 100,000 people each year in the United States. Patients can develop swelling, fatigue, high cholesterol and high blood pressure.

Achieving complete remission matters because it helps maintain kidney function over time. Remission can delay or prevent serious complications, including kidney failure, blood clots and cardiovascular disease.

The FDA granted Gazyva Breakthrough Therapy, Orphan Drug and Priority Review designations for this approval. Genentech noted the drug had previously received Breakthrough Therapy Designation for the disease.

What the MAJESTY trial showed

The approval rests on MAJESTY, a Phase III trial that randomized 142 adults. Patients received Gazyva or tacrolimus, a treatment sometimes used off-label for this disease, in a one-to-one split.

The trial was randomized, controlled, open-label and multicenter, with a main study period of 104 weeks. Its primary endpoint was complete remission of proteinuria at week 104.

Complete remission meant a urine protein-creatinine ratio of 0.3 grams per gram or less, with stable kidney filtration. Patients also had to avoid rescue therapy, treatment failure and early discontinuation.

At week 104, 36.1% of Gazyva patients reached complete remission, against 5.7% on tacrolimus. The adjusted difference was 31.1 percentage points, with a 95% confidence interval of 18.2 to 44.0, and p<0.001.

Overall remission, complete or partial, reached 50% on Gazyva at week 104, against 12.9% on tacrolimus. The adjusted difference was 37.8 percentage points, with a confidence interval of 23.9 to 51.8, and p<0.001.

Complete remission at week 76 was 36.1% on Gazyva, against 8.6% on tacrolimus. The adjusted difference was 27.4 percentage points, with a confidence interval of 13.4 to 39.8, and p<0.001.

Levi Garraway, Genentech's chief medical officer, said targeting B cells addresses "a critical underlying driver of disease." He said Gazyva offers "a more effective approach to help achieve durable disease control."

Garraway said the company is "turning decades of specialized antibody engineering into tangible outcomes for patients" with immune-mediated kidney diseases. He framed the result as significantly higher complete remission rates than tacrolimus achieved.

Marc Hurlbert, chief executive of the National Kidney Foundation, called the approval a milestone for patients and clinicians. He said it is "finally giving patients and clinicians more treatment options."

Teresa Graham, chief executive of Roche Pharmaceuticals, called the decision an important targeted treatment option for the pMN community. She said it widens the group of patients who may benefit from Gazyva.

Safety, warnings and how Gazyva works

Genentech said safety matched Gazyva's well-characterized profile, with no new safety signals identified. The FDA listed infusion-related reactions and upper respiratory tract infection as the most common side effects in the study.

The label carries boxed warnings for hepatitis B virus reactivation and for PML. PML, progressive multifocal leukoencephalopathy, is a rare and serious brain infection.

Gazyva is a humanized monoclonal antibody, a lab-engineered immune protein, that targets B cells. It binds CD20, a protein on certain B cells, through a Type II anti-CD20 region. A glycoengineered Fc region strengthens the resulting immune attack on those cells.

This is Gazyva's third FDA approval in immune-mediated kidney diseases, after idiopathic nephrotic syndrome and lupus nephritis. The drug was previously approved for certain cancers, active lupus nephritis and childhood-onset idiopathic nephrotic syndrome.

Gazyva is approved in 100 countries for various blood cancers. Its lupus nephritis approvals span more than 65 countries, according to Genentech.

What remains unknown

Genentech disclosed no price, launch timing or dosing schedule for the new indication in its release. The FDA notice also carried no pricing or launch detail, so patient access timing is unknown.

For patients, the practical questions are when treatment becomes available and what it will cost. Neither document answers them, and Genentech gave no timeline for first availability in the United States.

MAJESTY compared Gazyva with tacrolimus only, a drug used off-label for this disease. How Gazyva compares with other approaches doctors use today was not tested in this trial.

The MAJESTY results were presented in June 2026 and published in the New England Journal of Medicine. Whether other regulators follow the FDA remains open, though Genentech is submitting the data abroad.

The decisions that come next

What to watch: the FDA's decision on Gazyva for systemic lupus erythematosus, expected by December 2026. Genentech is also submitting the MAJESTY data to other health authorities, including the European Medicines Agency.

In Europe, the CHMP recently recommended approving Gazyva for systemic lupus erythematosus. A European Commission decision is expected in the near future, Genentech said.

Sources & evidence

Source checked2 sources · 8 figures

Figure receipts

Every figure in this article, with the source it came from.

  • 36.1 MAJESTY complete remission of proteinuria at week 104, Gazyva arm

    As of Nov. 16, 2026

  • 5.7 MAJESTY complete remission of proteinuria at week 104, tacrolimus arm

    As of Nov. 16, 2026

  • 31.1 MAJESTY adjusted difference in complete remission at week 104, Gazyva vs tacrolimus

    As of Nov. 16, 2026

  • 50 MAJESTY overall remission (complete or partial) at week 104, Gazyva arm

    As of Nov. 16, 2026

  • 36.1 MAJESTY complete remission at week 76, Gazyva arm

    As of Nov. 16, 2026

  • 142 MAJESTY Phase III randomized adults

    As of Nov. 16, 2026

  • 1.2 Estimated United States incidence of primary membranous nephropathy

    As of Nov. 16, 2026

  • 0.3 FDA complete-remission urine protein-creatinine ratio ceiling

    As of Nov. 16, 2026

As of Monday, Nov. 16, 2026.

TickerGrove house illustration for healthcare coverage: a double helix

Get the Morning Brief — Weekday Morning Brief · Saturday Weekend Brief · Sunday Week Ahead

Discuss this story. Join TickerGrove on Discord to talk companies, earnings, and markets, or request future coverage.

Disclaimer

TickerGrove is education and journalism only. It is not investment advice, not a broker-dealer, and not a recommendation to buy, sell, or hold any security.

Nothing on this site is a pick or a return promise. Official economic prints and company filings are dated observations. External quote links open a separate service; TickerGrove does not host those prices.

Companies · All stories